IL137146A0 - Hydroxamic and carboxylic acid derivatives - Google Patents
Hydroxamic and carboxylic acid derivativesInfo
- Publication number
- IL137146A0 IL137146A0 IL13714699A IL13714699A IL137146A0 IL 137146 A0 IL137146 A0 IL 137146A0 IL 13714699 A IL13714699 A IL 13714699A IL 13714699 A IL13714699 A IL 13714699A IL 137146 A0 IL137146 A0 IL 137146A0
- Authority
- IL
- Israel
- Prior art keywords
- hydroxamic
- carboxylic acid
- acid derivatives
- receptors
- tnf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
For the treatment of cancer, inflammation, and other conditions associated with matrix metalloproteinases or that are mediated by TNF alpha or enzymes involved in the shedding of L-selectin, CD23, the TNF receptors, IL-1 receptors, or IL-6 receptors, disclosed are compounds of the general formula B-X-(CH2)m-(CR1R2)n-W-COY.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9802073.8A GB9802073D0 (en) | 1998-01-30 | 1998-01-30 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
GBGB9819574.6A GB9819574D0 (en) | 1998-09-08 | 1998-09-08 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
PCT/GB1999/000313 WO1999038843A1 (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
US09/239,603 US6100266A (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IL137146A0 true IL137146A0 (en) | 2001-07-24 |
Family
ID=27269200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13714699A IL137146A0 (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
Country Status (18)
Country | Link |
---|---|
US (1) | US6100266A (en) |
EP (1) | EP1051395B1 (en) |
JP (1) | JP2002501943A (en) |
CN (1) | CN100402496C (en) |
AT (1) | ATE346041T1 (en) |
AU (1) | AU735929B2 (en) |
BR (1) | BR9908215A (en) |
CA (1) | CA2317455C (en) |
CY (1) | CY1106338T1 (en) |
DE (1) | DE69934094T2 (en) |
DK (1) | DK1051395T3 (en) |
ES (1) | ES2277424T3 (en) |
HK (1) | HK1029330A1 (en) |
HU (1) | HUP0100597A3 (en) |
IL (1) | IL137146A0 (en) |
NO (1) | NO326266B1 (en) |
PL (1) | PL200418B1 (en) |
WO (1) | WO1999038843A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
NZ515829A (en) | 1999-06-04 | 2003-10-31 | Astrazeneca Ab | Inhibitors of metalloproteinases |
JP2003519119A (en) * | 1999-12-24 | 2003-06-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | (Hetero) bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives |
AU2001232113A1 (en) * | 2000-02-21 | 2001-09-03 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
RU2283306C2 (en) | 2000-02-21 | 2006-09-10 | Астразенека Аб | Piperidine- and piperazine-substituted n-hydroxyformamides as inhibitors of metalloproteinases |
US20040024066A1 (en) * | 2000-05-25 | 2004-02-05 | Best Desmond John | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides |
FR2827859B1 (en) * | 2001-07-30 | 2005-09-23 | Lipha | 4- (ARYLTHIO) - OR 4- (HETEROARYLTHIO) -BUTYRIC DERIVATIVES IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DIABETES |
GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
WO2003022801A1 (en) | 2001-09-07 | 2003-03-20 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
GB0128378D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
GB0128376D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel compounds |
SE0301922D0 (en) * | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
AU2006316552B2 (en) * | 2005-11-24 | 2012-06-07 | Merck Serono Sa | N-hydroxyamide derivatives and use thereof |
DK2041181T3 (en) * | 2006-06-08 | 2011-08-29 | Helmholtz Zentrum Muenchen | Specific protease inhibitors and their use in cancer therapy |
CA2804918C (en) | 2010-07-08 | 2018-03-06 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and medicament containing same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
EP0826000B1 (en) * | 1995-05-10 | 2002-10-23 | Darwin Discovery Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses |
WO1997049679A1 (en) * | 1996-06-27 | 1997-12-31 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
ID21897A (en) * | 1996-09-27 | 1999-08-05 | Upjohn Co | ACID B-SULFONYL HYDROXYCAMM AS A MATERIAL HANDLING MATRIX METALOPROTEINASE |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US6476027B1 (en) * | 1997-03-04 | 2002-11-05 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
KR100419353B1 (en) * | 1997-07-31 | 2004-02-19 | 아보트 러보러터리즈 | N-Hydroxyformamide derivatives and a composition for inhibiting matrix metalloproteinases comprising the same |
-
1999
- 1999-01-29 AU AU22914/99A patent/AU735929B2/en not_active Ceased
- 1999-01-29 US US09/239,603 patent/US6100266A/en not_active Expired - Fee Related
- 1999-01-29 DE DE69934094T patent/DE69934094T2/en not_active Expired - Lifetime
- 1999-01-29 BR BR9908215-2A patent/BR9908215A/en not_active Application Discontinuation
- 1999-01-29 ES ES99902703T patent/ES2277424T3/en not_active Expired - Lifetime
- 1999-01-29 HU HU0100597A patent/HUP0100597A3/en unknown
- 1999-01-29 DK DK99902703T patent/DK1051395T3/en active
- 1999-01-29 WO PCT/GB1999/000313 patent/WO1999038843A1/en active IP Right Grant
- 1999-01-29 JP JP2000530080A patent/JP2002501943A/en active Pending
- 1999-01-29 AT AT99902703T patent/ATE346041T1/en active
- 1999-01-29 PL PL342184A patent/PL200418B1/en not_active IP Right Cessation
- 1999-01-29 EP EP99902703A patent/EP1051395B1/en not_active Expired - Lifetime
- 1999-01-29 IL IL13714699A patent/IL137146A0/en active IP Right Grant
- 1999-01-29 CN CNB998024937A patent/CN100402496C/en not_active Expired - Fee Related
- 1999-01-29 CA CA2317455A patent/CA2317455C/en not_active Expired - Fee Related
-
2000
- 2000-07-28 NO NO20003868A patent/NO326266B1/en not_active IP Right Cessation
- 2000-12-14 HK HK00108043A patent/HK1029330A1/en not_active IP Right Cessation
-
2007
- 2007-02-22 CY CY20071100255T patent/CY1106338T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE69934094T2 (en) | 2007-06-06 |
AU2291499A (en) | 1999-08-16 |
CN100402496C (en) | 2008-07-16 |
HK1029330A1 (en) | 2001-03-30 |
JP2002501943A (en) | 2002-01-22 |
NO20003868D0 (en) | 2000-07-28 |
DK1051395T3 (en) | 2007-04-02 |
NO326266B1 (en) | 2008-10-27 |
NO20003868L (en) | 2000-07-28 |
CA2317455C (en) | 2011-01-25 |
ES2277424T3 (en) | 2007-07-01 |
HUP0100597A3 (en) | 2001-12-28 |
CA2317455A1 (en) | 1999-08-05 |
ATE346041T1 (en) | 2006-12-15 |
AU735929B2 (en) | 2001-07-19 |
WO1999038843A1 (en) | 1999-08-05 |
EP1051395A1 (en) | 2000-11-15 |
CY1106338T1 (en) | 2011-10-12 |
PL200418B1 (en) | 2009-01-30 |
BR9908215A (en) | 2000-11-28 |
PL342184A1 (en) | 2001-05-21 |
HUP0100597A2 (en) | 2001-08-28 |
US6100266A (en) | 2000-08-08 |
CN1289322A (en) | 2001-03-28 |
DE69934094D1 (en) | 2007-01-04 |
EP1051395B1 (en) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL137146A0 (en) | Hydroxamic and carboxylic acid derivatives | |
EP1119362A4 (en) | Method of using tetracycline compounds to enhance interleukin-10 production | |
PL314300A1 (en) | Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases | |
FI971412A (en) | Peptididyl compounds and their therapeutic use as inhibitors of metalloproteases | |
YU6602A (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
CY1109328T1 (en) | THIENODIBENZOAZULENIUM COMPOUNDS AS TUMOR NECROSION FACTOR INHIBITORS | |
EP0863757A4 (en) | ||
NO20002440D0 (en) | Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity | |
MY109722A (en) | Azaoxindole derivatives. | |
MY133125A (en) | Novel dihydroxyhexanoic acid derivatives | |
BR0208694A (en) | Use of selective cox-2 inhibitors to treat urinary incontinence | |
GB0003025D0 (en) | Novel compounds | |
EA200200189A1 (en) | APPLICATION OF INTERLEUKIN INHIBITORS 18 | |
ATE247650T1 (en) | HYDROXAMIC ACID AND CARBOXIC ACID DERIVATIVES | |
AP2002002417A0 (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors. | |
ATE394117T1 (en) | USE OF CC CHEMOKINE CCL5/RANTES MUTANTS TO TREAT LIVER DISEASE | |
MX9706086A (en) | Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition. | |
IT1294932B1 (en) | USE OF SUBSTITUTED 2-AMINOTETHRALINE-6,7 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THE TREATMENT OF PATHOLOGIES | |
MX9704729A (en) | 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds. | |
MX9704740A (en) | 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |